Eli Lilly (LLY): FY25 Q3 earnings call, Oct 30, 2025
No Kalshi or Polymarket word markets were listed for Eli Lilly’s Oct 30, 2025 earnings call (FY25 Q3). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
2 matches for “Jaypirca”; 2 quoted, at least 25 words apart.
…for early symptomatic Alzheimer's disease. Positive results from Phase III trial of Jaypirca in treatment of naive CLL. Positive overall survival data for Verzenio in…
…data in ulcerative colitis show long-term safety and efficacy benefits. Within oncology, Jaypirca continued to build momentum both in the marketplace and with new data…
Agents: this page as TSV at /api/v1/appearances/eli-lilly:2025-10-30:earnings_call · words: /api/v1/brief?appearance=eli-lilly:2025-10-30:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP